Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Balke, Maurice ^a   Campanacci, Laura ^b   Gebert, Carsten ^a   Picci, Piero ^b   Gibbons, Max ^c   Taylor, Richard ^c   Hogendoorn, Pancras ^d   Kroep, Judith ^d   Wass, John ^c   Athanasou, Nicholas ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; PAMIDRONIC ACID; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CENTER; CANCER INHIBITION; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; MALE; OSTEOCLAST; OSTEOCLASTOMA; OSTEOLYSIS; PRIMARY TUMOR; SOFT TISSUE METASTASIS; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME; BONE TUMOR; CANCER INVASION; CLINICAL TRIAL; DRUG EFFECT; LUNG TUMOR; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; GIANT CELL TUMOR OF BONE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; OSTEOCLASTS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 77956462309     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-462     Document Type: Article

References (29)

1. Reid R, Bareyce SS, Sciot R. Giant cell tumour. Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, Lyon: IARC Press, Fletcher L, Unni U, Mertens F, 310, 312.
2. Unni KK, Inwards C, Bridge JA, Kindblom L-G, Wold LE. Tumours of the bones and joints. AFIP Atlas of Tumour Pathology Fourth Series, Fascicle 2, AFIP 2005,
3. Lau YS, Sabokbar A, Gibbons CLMH, Athanasou NA. Phenotypic and molecular studies on giant cell tumours of bone and soft tissues. Hum Pathol 2005, 36:945-954. 10.1016/j.humpath.2005.07.005, 16153456.
4. Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of Giant-Cell Tumours of Long Bones with curettage and bone-grafting. J Bone Joint Surg 1999, 81A:811-20.
5. Turcotte RE. Giant Cell Tumour. Orthop Clin North Am 2006, 37:35-41. 10.1016/j.ocl.2005.08.005, 16311110.
6. Campanacci M, Baldini N, Borian S, Sudanese A. Giant-cell tumour of bone. J Bone Joint Surg 1987, 68A:106-14.
7. Mendenhall WM, Ziotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumour of bone. Am J Clin Oncol 2006, 29:96-9. 10.1097/01.coc.0000195089.11620.b7, 16462511.
8. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998, 38:375-388. 10.1146/annurev.pharmtox.38.1.375, 9597160.
9. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007, 86:1022-1033. 10.1177/154405910708601102, 17959891.
10. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Mankonnen J, Firth JC. Cellular and molecular mechanisms and action of bisphosphonates. Cancer 2000, 88(12 Suppl):2961-2978. 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L, 10898340.
11. Lane JM, Safdar NK, O'Connor WJ, Nydlick M, Hommen JP, Schneider R, Tomin E, Brand J, Curtin J. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop 2001, 382:6-12. 10.1097/00003086-200101000-00003, 11154006.
12. Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997, 12:1746-1752. 10.1359/jbmr.1997.12.10.1746, 9333137.
13. Farran RP, Zaretski E, Egeler M. Treatment of Langerhans Cell Histiocytosis with pamidronate. J Pediatr Hematol 2001, 23:54-56.
14. Petra M, Gibbons CLMH, Athanasou NA. Bisphosphonate treatment of benign multifocal and unifocal primary osteolytic tumours of bone. Sarcoma 2003, 7:35-41. 10.1080/1357714031000114165, 2395513, 18521367.
15. Arpornchayanon O, Leerapun T. Effectiveness of intravenous bisphosphonates in treatment of giant cell tumour: a case report and review of the literature. J Med Assoc Thai 2008, 91:1609-12.
16. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumour of bone: a case-control study. Bone 2008, 42:68-73. 10.1016/j.bone.2007.08.038, 17962092.
17. Quinn J, Matsumura Y, Tarin D, McGee JO'D, Athanasou NA. Cellular and hormonal mechanisms associated with malignant bone resorption. Lab Invest 1994, 71:465-471.
18. Clohisy DR, Perkins SL, Romeraine MLR. Review of cellular mechanisms of tumour osteolysis. Clin Orthop 1998, 373:104-114.
19. Athanasou NA, Quinn J. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 43:997-1004. 10.1136/jcp.43.12.997, 502972, 2266187.
20. Hall EJ, Sylies NP. Analgesia for patients with advanced disease:2. Postgrad Med J 2004, 80:190-195. 10.1136/pgmj.2003.015529, 1742965, 15082837.
21. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce B. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Mineral Res 1995, 10:1478-1487.
22. Nishigawa M, Akatsu T, Katayama Y, Yasumato Y, Kado S, Kugai N, Yamamoto M, Nogata N. Bisphosphonates act on osteoblast cells and inhibit osteoclast formation in mouse marrow cutures. Bone 1996, 18:9-14. 10.1016/8756-3282(95)00426-2, 8717530.
23. Pandey R, Quinn J, Sabokbar A, Athanasou NA. Bisphosphonate inhibition of bone resorption by particulate biomaterial-associated macrophages. Acta Orthop Scand 1996, 67:221-228. 10.3109/17453679608994677, 8686457.
24. Chang SS, Suratwala SJ, Jung KM, Doppelt JD, Zhang HZ, Blaine TA, Kim TW, Winchester RJ, Lee FY. Bisphosphonates may reduce recurrence in giant cell tumour by inducing apoptosis. Clin Orthop Relat Res 2004, 426:103-9. 10.1097/01.blo.0000141372.54456.80, 15346059.
25. Cheng YY, Huan L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumour cells in giant cell tumour of bone. Calcif Tissue Int 2004, 75:71-7. 10.1007/s00223-004-0120-2, 15037971.
26. Cheng YY, Huang L, Kumta SM, Lee KM, Lai FM, Tam JS. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumour of bone following bisphosphonate administration. Ultrastruct Pathol 2003, 27:385-91.
27. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet (Oncol) 2010, 11:275-280. 10.1016/S1470-2045(10)70010-3, 20149736.
28. Reid IA. Osteonecrosis of the jaw. Skeletal Radiol 2009, 38:5-9. 10.1007/s00256-008-0549-x, 18649076.
29. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons C, Ooi W, Cello D. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain. J Pain Symptom Manage 2009, 38:244-257. 10.1016/j.jpainsymman.2008.08.005, 19364633.